Clinical Trial Detail

NCT ID NCT03815058
Title A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Genentech, Inc.
Indications

melanoma

Therapies

Pembrolizumab + RO7198457

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.